[48] Key Findings and Methodologies

Question 1

How are functional CAR T cells produced in vitro?

Answer 1

Using CD5-targeted LNPs carrying modified mRNA.

Question 2

What is the key evidence for CAR T cell functionality?

Answer 2

Observation of trogocytosis and successful engagement with FAP-expressing target cells.

Question 3

What is the significance of In vivo reprogramming?

Answer 3

Reprogramming of T cells to CAR T cells within the body, avoiding external modification.

Question 4

What were the in vivo tests focused on?

Answer 4

Efficiency and functionality of transient CAR T cells and improvement in cardiac function.

Question 5

What methods were used for CAR T cell production?

Answer 5

Lipid nanoparticles loaded with modified nucleoside-containing mRNA targeted to T lymphocytes.

Question 6

What measurements showed improvement in cardiac function?

Answer 6

Echocardiograph measurements indicating improvements in left ventricle volumes and both diastolic and systolic function.

Question 7

What model was used for testing?

Answer 7

Murine model of cardiac injury and fibrosis.

Question 8

What approach did the study take for CAR T cell production?

Answer 8

In vivo generation using mRNA technology and lipid nanoparticle packaging.